Healthcare provider profile · identity verified

Zehra Tosur, M.D.

Internal Medicine · HOUSTON, TX · NPI 1477971406

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	411	118
Amlodipine Besylate	Amlodipine Besylate	264	74
Losartan Potassium	Losartan Potassium	180	61
Levothyroxine Sodium	Levothyroxine Sodium	161	53
Omeprazole	Omeprazole	150	39
Carvedilol	Carvedilol	125	43
Rosuvastatin Calcium	Rosuvastatin Calcium	84	32
Metformin Hcl	Metformin Hcl	83	32
Lisinopril	Lisinopril	81	26
Trazodone Hcl	Trazodone Hcl	76	17
Hydrochlorothiazide	Hydrochlorothiazide	73	26
Gabapentin	Gabapentin	72	28
Ozempic	Semaglutide	68	14
Alendronate Sodium	Alendronate Sodium	64	23
Allopurinol	Allopurinol	61	18
Metformin Hcl Er	Metformin Hcl	61	19
Fluticasone Propionate	Fluticasone Propionate	59	27
Escitalopram Oxalate	Escitalopram Oxalate	58	19
Clopidogrel	Clopidogrel Bisulfate	54	15
Jardiance	Empagliflozin	54	17
Furosemide	Furosemide	53	22
Metoprolol Succinate	Metoprolol Succinate	50	16
Meloxicam	Meloxicam	48	13
Albuterol Sulfate Hfa	Albuterol Sulfate	43	17
Ezetimibe	Ezetimibe	42	15
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	42	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	suppressed
Montelukast Sodium	Montelukast Sodium	41	11
Solifenacin Succinate	Solifenacin Succinate	41	suppressed
Nifedipine Er	Nifedipine	40	13
Pantoprazole Sodium	Pantoprazole Sodium	40	14
Sertraline Hcl	Sertraline Hcl	40	suppressed
Simvastatin	Simvastatin	40	12
Famotidine	Famotidine	38	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	35	suppressed
Januvia	Sitagliptin Phosphate	34	suppressed
Pravastatin Sodium	Pravastatin Sodium	33	13
Bupropion Xl	Bupropion Hcl	31	suppressed
Synthroid	Levothyroxine Sodium	29	suppressed
Spironolactone	Spironolactone	28	12
Duloxetine Hcl	Duloxetine Hcl	25	11
Buspirone Hcl	Buspirone Hcl	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Glimepiride	Glimepiride	22	suppressed
Sod Sulf-Potass Sulf-Mag Sulf	Sodium, Potassium,mag Sulfates	21	21
Valsartan	Valsartan	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	20	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Azithromycin	Azithromycin	19	18
Farxiga	Dapagliflozin Propanediol	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Estradiol	Estradiol	17	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Nystatin	Nystatin	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Finasteride	Finasteride	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	11
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Atenolol	Atenolol	14	suppressed
Glipizide	Glipizide	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Eliquis	Apixaban	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Risedronate Sodium	Risedronate Sodium	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error